FR2520619A1 - Composition revertante basee sur l'association polyethylene glycol-dimethylsulfoxyde-theophylline et son emploi en cancerologie - Google Patents
Composition revertante basee sur l'association polyethylene glycol-dimethylsulfoxyde-theophylline et son emploi en cancerologie Download PDFInfo
- Publication number
- FR2520619A1 FR2520619A1 FR8201397A FR8201397A FR2520619A1 FR 2520619 A1 FR2520619 A1 FR 2520619A1 FR 8201397 A FR8201397 A FR 8201397A FR 8201397 A FR8201397 A FR 8201397A FR 2520619 A1 FR2520619 A1 FR 2520619A1
- Authority
- FR
- France
- Prior art keywords
- polyethylene glycol
- theophylline
- dimethylsulfoxide
- cells
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000278 theophylline Drugs 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- -1 POLYETHYLENE Polymers 0.000 title 1
- 239000004698 Polyethylene Substances 0.000 title 1
- 229920000573 polyethylene Polymers 0.000 title 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims abstract description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 36
- 238000000338 in vitro Methods 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 230000009466 transformation Effects 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 2
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000030944 contact inhibition Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000200 toxicological information Toxicity 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8201397A FR2520619A1 (fr) | 1982-01-29 | 1982-01-29 | Composition revertante basee sur l'association polyethylene glycol-dimethylsulfoxyde-theophylline et son emploi en cancerologie |
| DE8383400095T DE3370283D1 (en) | 1982-01-29 | 1983-01-14 | Composition for tumour reversion and its use in cancerology |
| EP83400095A EP0086122B1 (fr) | 1982-01-29 | 1983-01-14 | Composition destinée à réaliser la reversion tumorale et son emploi en cancérologie |
| DE198383400095T DE86122T1 (de) | 1982-01-29 | 1983-01-14 | Zusammensetzung zur tumorumkehrung und ihre verwendung in der krebsforschung. |
| CA000419788A CA1188226A (en) | 1982-01-29 | 1983-01-19 | Composition for achieving tumor reversion and its use in cancerology |
| ZA83396A ZA83396B (en) | 1982-01-29 | 1983-01-20 | A composition for achieving tumor reversion and its use in cancerology |
| IL67748A IL67748A (en) | 1982-01-29 | 1983-01-25 | Compositions comprising polyethylene glycol,dimethyl sulfoxide and theophylline for achieving tumor reversion |
| JP58011585A JPS58146510A (ja) | 1982-01-29 | 1983-01-28 | 癌正常化組成物 |
| US06/883,300 US4767763A (en) | 1982-01-29 | 1986-07-07 | Composition for achieving tumor reversion and its use in cancerology for dogs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8201397A FR2520619A1 (fr) | 1982-01-29 | 1982-01-29 | Composition revertante basee sur l'association polyethylene glycol-dimethylsulfoxyde-theophylline et son emploi en cancerologie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2520619A1 true FR2520619A1 (fr) | 1983-08-05 |
| FR2520619B1 FR2520619B1 (en, 2012) | 1984-04-06 |
Family
ID=9270449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8201397A Granted FR2520619A1 (fr) | 1982-01-29 | 1982-01-29 | Composition revertante basee sur l'association polyethylene glycol-dimethylsulfoxyde-theophylline et son emploi en cancerologie |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4767763A (en, 2012) |
| EP (1) | EP0086122B1 (en, 2012) |
| JP (1) | JPS58146510A (en, 2012) |
| CA (1) | CA1188226A (en, 2012) |
| DE (2) | DE86122T1 (en, 2012) |
| FR (1) | FR2520619A1 (en, 2012) |
| IL (1) | IL67748A (en, 2012) |
| ZA (1) | ZA83396B (en, 2012) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9417742D0 (en) * | 1994-09-03 | 1994-10-19 | Univ Nottingham | Macrophage stimulating composition |
| JP2008308473A (ja) * | 2007-06-18 | 2008-12-25 | Japan Health Science Foundation | 癌治療剤 |
| FR3012037B1 (fr) * | 2013-10-23 | 2016-05-20 | Herve Edouard Henri Jeambourquin | Solution révertante à base de diméthylsulfoxyde et de polyéthylène-glycol |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1043012A (en) * | 1964-07-28 | 1966-09-21 | Ici Ltd | Pharmaceutical compositions comprising tumour-growth-inhibitory agents |
| CA824650A (en) * | 1969-10-07 | Desjardins Roger | Suppository |
-
1982
- 1982-01-29 FR FR8201397A patent/FR2520619A1/fr active Granted
-
1983
- 1983-01-14 DE DE198383400095T patent/DE86122T1/de active Pending
- 1983-01-14 DE DE8383400095T patent/DE3370283D1/de not_active Expired
- 1983-01-14 EP EP83400095A patent/EP0086122B1/fr not_active Expired
- 1983-01-19 CA CA000419788A patent/CA1188226A/en not_active Expired
- 1983-01-20 ZA ZA83396A patent/ZA83396B/xx unknown
- 1983-01-25 IL IL67748A patent/IL67748A/xx not_active IP Right Cessation
- 1983-01-28 JP JP58011585A patent/JPS58146510A/ja active Granted
-
1986
- 1986-07-07 US US06/883,300 patent/US4767763A/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA824650A (en) * | 1969-10-07 | Desjardins Roger | Suppository | |
| GB1043012A (en) * | 1964-07-28 | 1966-09-21 | Ici Ltd | Pharmaceutical compositions comprising tumour-growth-inhibitory agents |
Non-Patent Citations (1)
| Title |
|---|
| CA1982 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58146510A (ja) | 1983-09-01 |
| DE86122T1 (de) | 1983-11-24 |
| DE3370283D1 (en) | 1987-04-23 |
| IL67748A (en) | 1986-01-31 |
| EP0086122B1 (fr) | 1987-03-18 |
| EP0086122A1 (fr) | 1983-08-17 |
| IL67748A0 (en) | 1983-05-15 |
| CA1188226A (en) | 1985-06-04 |
| FR2520619B1 (en, 2012) | 1984-04-06 |
| US4767763A (en) | 1988-08-30 |
| JPH0460093B2 (en, 2012) | 1992-09-25 |
| ZA83396B (en) | 1983-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7315243B2 (ja) | エクソソームの製造方法 | |
| Meyer | Commodities and the power of prayer: Pentecostalist attitudes towards consumption in contemporary Ghana | |
| Teramura et al. | Improvement of graft survival by surface modification with poly (ethylene glycol)-lipid and urokinase in intraportal islet transplantation | |
| Rao et al. | Nanoparticle-mediated intracellular delivery enables cryopreservation of human adipose-derived stem cells using trehalose as the sole cryoprotectant | |
| Chen et al. | Co-immobilization of urokinase and thrombomodulin on islet surfaces by poly (ethylene glycol)-conjugated phospholipid | |
| CA2990348C (fr) | Procede de cryoconservation de cellules a visee therapeutique | |
| US20240352079A1 (en) | Silk-Based Products, Formulations, and Methods of Use | |
| Harris et al. | Th1–Th2 polarisation and autophagy in the control of intracellular mycobacteria by macrophages | |
| Shaw et al. | Mesenchymal stromal cells: an antimicrobial and host-directed therapy for complex infectious diseases | |
| JPH09503225A (ja) | 粒状物質を含むリポソーム | |
| FR2601591A1 (fr) | Preparation pharmaceutique stable contenant un facteur de stimulation de la lignee granulocytaire, et procede pour la production de celle-ci | |
| CN109475508A (zh) | 具有增强的热稳定性的含有生物活性材料的速溶薄膜的制备方法 | |
| FR2840532A1 (fr) | Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s) | |
| CA2384768A1 (fr) | Methodes et compositions pour la conservation de chondrocytes et utilisations | |
| CN102548562A (zh) | 眼科组合物 | |
| CN109517787A (zh) | 一种快速冻存和复苏子宫内膜干细胞的方法 | |
| Asif et al. | Heparinization of cell surfaces with short peptide-conjugated PEG-lipid regulates thromboinflammation in transplantation of human MSCs and hepatocytes | |
| CN100430049C (zh) | 分子表达功能抑制剂 | |
| CA3076610A1 (en) | Methods and compositions for the treatment of epidermolysis bullosa | |
| CA2475437A1 (fr) | Procedes de production de lymphocytes .gamma..delta.t | |
| Bellio et al. | Systemic delivery of large-scale manufactured Wharton’s Jelly mesenchymal stem cell-derived extracellular vesicles improves cardiac function after myocardial infarction | |
| FR2520619A1 (fr) | Composition revertante basee sur l'association polyethylene glycol-dimethylsulfoxyde-theophylline et son emploi en cancerologie | |
| Nabila et al. | The influence of surface charge on the antiviral effect of curcumin loaded in nanocarrier system | |
| Ghazi et al. | Decoding the secret of extracellular vesicles in the immune tumor microenvironment of the glioblastoma: On the border of kingdoms | |
| EP3316895B1 (fr) | Procédé de cryoconservation de cellules à visée thérapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |